These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23888956)

  • 21. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
    Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
    Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
    Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
    Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
    Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
    Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
    Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
    Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
    Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
    Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
    PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
    Klein JM; Henke A; Sauer M; Bessler M; Reiners KS; Engert A; Hansen HP; von Strandmann EP
    PLoS One; 2013; 8(11):e79502. PubMed ID: 24278143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC as a therapeutic target for treatment of endometrial cancers.
    Ren J; Zhang J; Cai H; Li Y; Zhang Y; Zhang X; Zhao D; Li Z; Ma H; Wang J; Gao YE; Xiao L; Liu R; Qian J; Liu Y; Wei H; Li J
    Curr Pharm Des; 2014; 20(11):1847-56. PubMed ID: 23888962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
    Prystowsky MB; Adomako A; Smith RV; Kawachi N; McKimpson W; Atadja P; Chen Q; Schlecht NF; Parish JL; Childs G; Belbin TJ
    J Pathol; 2009 Aug; 218(4):467-77. PubMed ID: 19402126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
    Xu M; Hong M; Xie H
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Oct; 33(10):1409-15. PubMed ID: 24144737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
    Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.
    Gandesiri M; Chakilam S; Ivanovska J; Benderska N; Ocker M; Di Fazio P; Feoktistova M; Gali-Muhtasib H; Rave-Fränk M; Prante O; Christiansen H; Leverkus M; Hartmann A; Schneider-Stock R
    Apoptosis; 2012 Dec; 17(12):1300-15. PubMed ID: 23011180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
    Saitoh Y; Bureta C; Sasaki H; Nagano S; Maeda S; Furukawa T; Taniguchi N; Setoguchi T
    Mol Carcinog; 2019 Feb; 58(2):234-246. PubMed ID: 30303565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
    Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
    Takai N; Desmond JC; Kumagai T; Gui D; Said JW; Whittaker S; Miyakawa I; Koeffler HP
    Clin Cancer Res; 2004 Feb; 10(3):1141-9. PubMed ID: 14871994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.
    Kim IA; No M; Lee JM; Shin JH; Oh JS; Choi EJ; Kim IH; Atadja P; Bernhard EJ
    Radiother Oncol; 2009 Jul; 92(1):125-32. PubMed ID: 19329208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
    PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.
    García-Guerrero E; Gogishvili T; Danhof S; Schreder M; Pallaud C; Pérez-Simón JA; Einsele H; Hudecek M
    Blood; 2017 Jun; 129(25):3386-3388. PubMed ID: 28476749
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.